{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:33:45Z","timestamp":1779237225526,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1089","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obesity is a disease that has historically eluded effective medical therapy. Prior to 2012, phentermine and orlistat were the only medications available to treat obesity in the USA, with phentermine approved only for short-term use. However, as of 2015, the repertoire of pharmacological agents available to treat obesity has greatly expanded to include four new drugs: lorcaserin, phentermine\/topiramate extended release (ER), naltrexone ER\/wellbutrin ER and liraglutide. Each has a unique mechanism of action and all are intended for long-term use. These newer medications share a common strategy to promote weight loss in that they are designed to manipulate the control of hunger and satiety in the central nervous system. Interestingly, the majority of these new agents are combinations of older medications that have been used for conditions other than obesity. The amount of weight loss seen with these agents beyond placebo varies but generally falls in the range of 3\u201310% of starting weight and requires continual use of the drug in order for weight loss to be sustained. In addition, each drug has a unique side effect profile that should be carefully considered when selecting the best agent for a given individual. This article provides a review of these recently approved medications focusing on efficacy, side effect profiles and appropriate application to the individual patient.<\/jats:p>","DOI":"10.1136\/postgradmedj-2015-133388","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T05:21:39Z","timestamp":1460006499000},"page":"401-406","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Drugs to treat obesity: do they work?"],"prefix":"10.1093","volume":"92","author":[{"given":"Sarah","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"2023041308550497700_"},{"key":"2023041308550497700_"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MCO.0b013e32833ae702","article-title":"Update on the pathophysiology of obesity","volume":"13","author":"Abumrad","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","article-title":"The medical care costs of obesity: an instrumental variables approach","volume":"31","author":"Cawley","year":"2012","journal-title":"J Health Econ"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","article-title":"The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003\u20132012","volume":"149","author":"Chang","year":"2014","journal-title":"JAMA Surg"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature14177","article-title":"Genetic studies of body mass index yield new insights for obesity biology","volume":"518","author":"Locke","year":"2015","journal-title":"Nature"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/clpt.2013.204","article-title":"Antiobesity pharmacotherapy: new drugs and emerging targets","volume":"95","author":"Kim","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.2010.57","article-title":"Central and peripheral molecular targets for antiobesity pharmacotherapy","volume":"87","author":"Valentino","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"179674","DOI":"10.1155\/2011\/179674","article-title":"Pharmacotherapies for obesity: past, current, and future therapies","volume":"2011","author":"Ioannides-Demos","year":"2011","journal-title":"J Obes"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1749-6632.2003.tb03177.x","article-title":"Central serotonin and melanocortin pathways regulating energy homeostasis","volume":"994","author":"Heisler","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cob.12075","article-title":"Orlistat-induced fulminant hepatic failure","volume":"4","author":"Sall","year":"2014","journal-title":"Clin Obes"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1345\/aph.1R779","article-title":"New obesity agents: lorcaserin and phentermine\/topiramate","volume":"47","author":"Fleming","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0024-3205(79)90222-4","article-title":"Suppression of appetitive behavior in the rat by naloxone: lack of effect of prior morphine dependence","volume":"24","author":"Holtzman","year":"1979","journal-title":"Life Sci"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1172\/JCI118017","article-title":"Effects of opioid antagonists naloxone and naltrexone on neuropeptide Y-induced feeding and brown fat thermogenesis in the rat. Neural site of action","volume":"96","author":"Kotz","year":"1995","journal-title":"J Clin Invest"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1517\/14656560903048959","article-title":"Naltrexone for the treatment of obesity: review and update","volume":"10","author":"Lee","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"2023041308550497700_","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2023041308550497700_","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","author":"Diabetes Prevention Program Research G","year":"2015","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/92\/1089\/401\/49846857\/postgradmedj-92-401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/92\/1089\/401\/49846857\/postgradmedj-92-401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:07:29Z","timestamp":1718464049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/92\/1089\/401\/6984289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":36,"journal-issue":{"issue":"1089","published-online":{"date-parts":[[2016,4,6]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2015-133388","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7]]},"published":{"date-parts":[[2016,4,6]]}}}